Clinical & Experimental Metastasis

, Volume 18, Issue 2, pp 171–178 | Cite as

Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro

  • Malika Balduyck
  • Farid Zerimech
  • Valérie Gouyer
  • Raphael Lemaire
  • Brigitte Hemon
  • Georges Grard
  • Carole Thiebaut
  • Véronique Lemaire
  • Evelyne Dacquembronne
  • Thérèse Duhem
  • Anne Lebrun
  • Marie-José Dejonghe
  • Guillemette Huet
Article

Abstract

Several matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) were studied in highly invasive (MDA-MB-231) and slightly invasive (MCF-7, T47D, BT-20) breast cancer cell lines. Investigations were carried out at the protein level and/or at the mRNA level, either in cells cultured as monolayers on plastic, or in cells seeded on a thin layer of Matrigel basement membrane matrix. Analysis of MMP expression by RT-PCR showed expression of MMP-1, MMP-3, and MMP-13 in highly invasive MDA-MB-231 cells, but not in slightly invasive cell lines. The extracellular secretion of MMP-1 and MMP-3 by MDA-MB 231 cells could be also shown by ELISA. TIMP-1 and TIMP-2 mRNAs were found in all cell lines, however, the extracellular secretion of both TIMPs was much higher in MDA-MB-231 cells than in the other cell lines. When the cells were cultured on Matrigel matrix, MMP-9 expression was induced in MDA-MB-231 cells only, as assessed by RT-PCR and zymography experiments. The invasive potential of MDA-MB-231 cells evaluated in vitro through Matrigel was significantly inhibited by the MMP inhibitor BB-2516, by 25% and 50% at the concentrations of 2 × 10−6M and 10−5M, respectively. In conclusion, our data show that highly invasive MDA-MB-231 cells but not slightly invasive T47D, MCF-7 and BT-20 cells express MMP-1, MMP-3, MMP-9 and MMP-13. MMP-9 which is specifically up-regulated by cell contact to Matrigel, may play a key role in the invasiveness of MDA-MB-231 cells through basement membranes.

metalloproteinases breast cancer cells invasiveness tissue inhibitors of metalloproteinases synthetic inhibitors of metalloproteinases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1: 99–106.PubMedGoogle Scholar
  2. 2.
    Woessner JFJ. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145–54.PubMedGoogle Scholar
  3. 3.
    Pei D, Majmudar G, Weiss SJ. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 1994; 269: 25849–55.PubMedGoogle Scholar
  4. 4.
    Noel A, Boulay A, Kebers F et al. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 2000; 19: 1605–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Sato H, Takino T, Kinoshita T et al. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett 1996; 385: 238–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Strongin AY, Collier I, Bannikov G et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Monteagudo C, Merino MJ, San-Juan J et al. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990; 136: 585–92.PubMedGoogle Scholar
  9. 9.
    Onisto M, Riccio MP, Scannapieco P et al. Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Int J Cancer 1995; 63: 621–6.PubMedGoogle Scholar
  10. 10.
    Engel G, Heselmeyer K, Aver G et al. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 1994; 58: 830–5.PubMedGoogle Scholar
  11. 11.
    Ahmad A, Hanby A, Dublin E et al. Stromelysin 3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol 1998; 152: 721–8.PubMedGoogle Scholar
  12. 12.
    Freije JM, Diez-Itza I, Balbin M et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766–73.PubMedGoogle Scholar
  13. 13.
    Ueno H, Nakamura H, Inoue M et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997; 57: 2055–60.PubMedGoogle Scholar
  14. 14.
    Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999; 189: 161–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Ree AH, Florenes VA, Berg JP et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997; 3: 1623–8.PubMedGoogle Scholar
  16. 16.
    McCarthy K, Maguire T, McGreal G et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999; 84: 44–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Remacle A, McCarthy K, Noel A et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000; 89: 118–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Basset P, Bellocq JP, Wolf C et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699–704.PubMedCrossRefGoogle Scholar
  19. 19.
    Wolf C, Rouyer N, Lutz Y et al. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 1993; 90: 1843–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Okada A, Bellocq J, Rouyer N et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995; 92: 2730–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Heppner KJ, Matrisian LM, Jensen RA et al. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273–82.PubMedGoogle Scholar
  22. 22.
    Nakopoulou L, Giannopoulou I, Gakiopoulou H et al. Matrix metalloproteinase-1 and-3 in breast cancer: Correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 1999; 30: 436–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Nielsen B, Sehested M, Kjeldsen L et al. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 1997; 77: 345–55.PubMedGoogle Scholar
  24. 24.
    Giambernardi TA, Grant GM, Taylor GP et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998; 16: 483–96.PubMedCrossRefGoogle Scholar
  25. 25.
    Mackay AR, Ballin M, Pelina MD et al. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 1992; 12: 168–84.PubMedGoogle Scholar
  26. 26.
    Gilles C, Polette M, Birembaut P et al. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis 1997; 15: 519–26.PubMedCrossRefGoogle Scholar
  27. 27.
    Pulyaeva H, Bueno J, Polette M et al. MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis 1997; 15: 111–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Nutt JE, Lunec J. Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells. Eur J Cancer 1996; 32A: 2127–35.PubMedCrossRefGoogle Scholar
  29. 29.
    Kim J, Yu W, Kovalski K et al. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998; 94: 353–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Shao ZM, Wu J, Shen ZZ et al. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 1998; 58: 4851–7.PubMedGoogle Scholar
  31. 31.
    Kolkhorst V, Sturzebecher J, Wiederanders B. Inhibition of tumour cell invasion by protease inhibitors: Correlation with the protease profile. J Cancer Res Clin Oncol 1998; 124: 598–606.PubMedCrossRefGoogle Scholar
  32. 32.
    Hahn-Dantona E, Ramos-DeSimone N, Sipley J et al. Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann NY Acad Sci 1999; 878: 372–87.PubMedCrossRefGoogle Scholar
  33. 33.
    Stonelake PS, Jones CE, Neoptolemos JP et al. Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines. Br J Cancer 1997; 75: 951–9.PubMedGoogle Scholar
  34. 34.
    Yang M, Kurkinen M. Different mechanisms of regulation of the human stromelysin and collagenase genes. Analysis by a reversetranscription-coupled-PCR assay. Eur J Biochem 1994; 222: 651–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Nuovo GJ, MacConnell PB, Simsir A et al. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55: 267–75.PubMedGoogle Scholar
  36. 36.
    Yoshimoto M, Itoh F, Yamamoto H et al. Expression of MMP-7(PUMP-1) mRNA in human colorectal cancers. Int J Cancer 1993; 54: 614–8.PubMedGoogle Scholar
  37. 37.
    Reboul P, Pelletier JP, Tardif G et al. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest 1996; 97: 2011–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Thompson EW, Paik S, Brunner N et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992; 150: 534–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781–92.PubMedGoogle Scholar
  40. 40.
    Tremble P, Damsky CH, Werb Z. Components of the nuclear signaling cascade that regulate collagenase gene expression in response to integrin-derived signals. J Cell Biol 1995; 129: 1707–20.PubMedCrossRefGoogle Scholar
  41. 41.
    Sudbeck BD, Pilcher BK, Welgus HG et al. Induction and repression of collagenase-1 by keratinocytes is controlled by distinct components of different extracellular matrix compartments. J Biol Chem 1997; 272: 22103–10.PubMedCrossRefGoogle Scholar
  42. 42.
    Sarkissian M, Lafyatis R. Integrin engagement regulates proliferation and collagenase expression of rheumatoid synovial fibroblasts. J Immunol 1999; 162: 1772–9.PubMedGoogle Scholar
  43. 43.
    Gilles C, Polette M, Seiki M et al. Implication of collagen type Iinduced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 1997; 76: 651–60.PubMedGoogle Scholar
  44. 44.
    Larjava H, Lyons JG, Salo T et al. Anti-integrin antibodies induce type IV collagenase expression in keratinocytes. J Cell Physiol 1993; 157: 190–200.PubMedCrossRefGoogle Scholar
  45. 45.
    Daemi N, Thomasset N, Lissitzky JC et al. Anti-beta4 integrin antibodies enhance migratory and invasive abilities of human colon adenocarcinoma cells and their MMP-2 expression. Int J Cancer 2000; 85: 850–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Will H, Atkinson SJ, Butler GS et al. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem 1996; 271: 17119–23.PubMedCrossRefGoogle Scholar
  47. 47.
    Pei D, Weiss SJ. Transmembrane-deletion mutants of the membranetype matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996; 271: 9135–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Docherty AJ, Lyons A, Smith BJ et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985; 318: 66–69.PubMedCrossRefGoogle Scholar
  49. 49.
    Knauper V, Smith B, Lopez-Otin C et al. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). Eur J Biochem 1997; 248: 369–73.PubMedCrossRefGoogle Scholar
  50. 50.
    Nagase H, Enghild JJ, Suzuki K et al. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 1990; 29: 5783–89.PubMedCrossRefGoogle Scholar
  51. 51.
    Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 1995; 270: 18506–11.PubMedCrossRefGoogle Scholar
  52. 52.
    Knauper V, Will H, Lopez-Otin C et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation-evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 1996; 271: 17124–31.PubMedCrossRefGoogle Scholar
  53. 53.
    Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogenactivated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998; 58: 1135–9.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Malika Balduyck
    • 1
  • Farid Zerimech
    • 1
  • Valérie Gouyer
    • 1
  • Raphael Lemaire
    • 2
  • Brigitte Hemon
    • 3
  • Georges Grard
    • 1
  • Carole Thiebaut
    • 1
  • Véronique Lemaire
    • 1
  • Evelyne Dacquembronne
    • 1
  • Thérèse Duhem
    • 1
  • Anne Lebrun
    • 1
  • Marie-José Dejonghe
    • 3
  • Guillemette Huet
    • 1
  1. 1.Laboratoire de BiochimieHôpital Claude HuriezLille CedexFrance
  2. 2.The Arthritis Center – Bldg. K-5Boston University School of MedicineBostonUSA
  3. 3.Unité INSERM 377Lille CedexFrance

Personalised recommendations